The prostate is an androgen-regulated organ, which has led to longstanding interest in the role of androgens in prostate carcinogenesis. Although evidence of a hormonal etiology for prostate cancer is strong, it is almost entirely circumstantial. Much of the problem in proving a causal relationship relates to the continued difficulties in reliably measuring human tissue-specific exposure to endogenous steroid hormones. The international and racial-ethnic variations in prostate cancer incidence, combined with the effects of migration on risk patterns, have suggested that genetic factors play a central role in determining prostate cancer risk. We are developing a polygenic model of prostate carcinogenesis, focused around a series of genes involved in androgen biosynthesis, transport and metabolism. We have begun to develop this model by utilizing sequence variants to study how polymorphic markers in two genes (SRD5A2 and AR) are related to prostate cancer risk within and between racial-ethnic groups. We are now collaborating with the Whitehead Institute/MIT, Center for Genome Research, to screen for single nucleotide polymorphisms in additional genes relevant to the androgen pathway and prostate cell growth. The model when fully developed can potentially provide a basis for targeting populations for screening interventions and for implementing primary preventive strategies.
The scientific community has been interested in the possible role of steroid hormones in cancer development for over 50 years [1, 2] . During that period, extraordinary amounts of indirect evidence has accumulated for a role of such hormones in the etiology of multiple human cancers [3] . Although there is some evidence that hormonal secretion and metabolism can be environmentally influenced, for example through dietary change, the control of hormonal patterns is also genetically regulated. Based on the extensive evidence of the hormone dependency of human prostate cancer, we are developing a polygenic model of prostate cancer susceptibility. We describe below the rationale on which this prostate cancer model is being built, the current model, and preliminary data that we and others have accumulated in support of this model. We also describe future research directions designed to expand the model to capture additional genes.
Prostate Cancer Epidemiology
By far the two most important risk factors for prostate cancer are age and race-ethnicity. Prostate cancer is extremely rare prior to age 40, but the rate of increase with aging is greater than for any other cancer; rates increase at approximately the 9-10th power of age [4] . For prostate cancer the rate of increase is steepest early in the agespecific curve and then gradually dissipates with age. This contrasts with some other epithelial cancers, such as colon and lung cancer, for which the relationship between age and incidence is strictly linear in log-log units.
African-American men have long been known to have the highest rates of prostate cancer in the world. Although rates vary somewhat among African-Americans across the US, rates average about 50-70% higher in African-Americans than whites [5] . The ratio of African-American to white incidence rates is highest early in the age-incidence cancers and then dissipates some with aging. Although historically there has been no totally adequate comparative data on prostate cancer rates among blacks in Africa, there is some recent data suggesting high rates of prostate cancer in some African populations [6] . Confirmation of these findings would support a strong genetic component to prostate cancer risk.
On the other end of the international and racial-ethnic spectrum of prostate cancer incidence, native Japanese and Chinese men (and probably other Asian populations such as Koreans) have the lowest prostate cancer rates in the world. Historically, it has been reported that the difference in incidence between African-Americans, on the one hand, and these native Asian populations, on the other, was approximately 50-fold [5] . We have, however, previously demonstrated that a major part of this difference is due to different detection strategies for prostate cancer between populations, and that the true difference in incidence is on the order of only 2-to 3-fold [7] . Nonetheless, Japanese-and Chinese-Americans have rates somewhat above those of men in their respective homelands, but their prostate cancer incidence rates never approach those of White Americans, much less African-Americans, even though Japanese, in particular, represent a highly acculturated immigrant population in the US [8] .
Androgens and Prostate Cancer
Over the past two decades, we have published several detailed articles on the role of steroid hormones in carcinogenesis [3, 9] . Steroid hormones play a critical role in controlling cell proliferation in their primary target organs, and increased cell proliferation appears to be a common denominator in the pathogenesis of much human cancer [10] , as this is a necessary event for the genetic changes required to activate proto-oncogenes or inactivate tumor suppressor genes. Genetic or environmental factors which alter the hormonal environment and, thus, the underlying rates of cell division in these target organs, would be expected to alter the underlying rate of malignant transformation in these target tissues as well [3] .
The prostate is a hormonally regulated organ. Testosterone (T) diffuses freely into prostate cells where it is converted to its metabolically more active form, dihydrotestosterone (DHT), through the activity of the enzyme, steroid 5·-reductase type II. DHT (and with less binding affinity T) binds to the androgen receptor (AR); this complex binds to DNA resulting in transactivation of genes with androgen-responsive elements, including those that control cell division [11] .
Among mammalian species, only men and dogs have a high naturally occurring incidence of prostate cancer [11] , and prostate cancer has proven difficult to produce experimentally. This lack of both experimental and naturally occurring models of the disease has dampened progress in understanding the pathogenesis of prostate cancer. The first experimental model of prostate adenocarcinoma (the human histologic equivalent) was produced by Noble [12] in 1977, through administration of T subcutaneously, and all subsequent models have had at least some androgen requirement for tumor induction or progression.
Prostate cancer is androgen-dependent and androgen ablation or blockade have been a mainstay of treatment for early metastatic prostate cancer for decades [5] . It is widely believed that men with highly underdeveloped prostates, such as eunuchs or men with constitutional 5·-reductase deficiency, never develop prostate cancer [5] .
While studies of hormone levels and prostate cancer risk are inherently complex due to inter-and intra-assay variability, cyclical and sporadic variations in the target hormone and the requirement for large prospective studies to name a few, one well-conducted prospective study recently found that prediagnostic circulating T levels were strongly predictive for prostate cancer development [13] . In that study, a strong trend of increasing prostate cancer risk with increasing levels of circulating free T was observed (risks by quartile were 1.0 (low), 1.4, 2.0 and 2.6 (high), p = 0.004 for trend).
As racial-ethnic variation in incidence is such a powerful feature of prostate cancer epidemiology, we have explored over the past decade whether there exist underlying differences in the androgen milieu of populations in the middle and at the extremes of prostate cancer incidence. We reported that T levels were higher in healthy young adult African-American than white men [14] . We later extended this study of hormone patterns in AfricanAmerican and white men to include young Japanese men born and raised in rural Japan, a group of men with low expected lifetime risk of prostate cancer. These young Japanese men had T levels which did not differ significantly from either African-Americans or whites. However, in this extended study, we found that the Japanese men had circulating levels of 3·-androstanediol glucuronide, an index of in vivo 5·-reductase which was 25-35% lower than the African-American men and white men [15] . Chinese men in Hong Kong have been shown to have similarly low levels of this androgen metabolite [16] .
These differences in prostate cancer incidence among African-Americans, US whites and Asians (Chinese, Japanese) might be explained by differences in T biosynthesis on the one hand, and T metabolism on the other. These T differences could be due to environmental influences, genetic control, or an interplay of genetic and environmental factors; we have initially focused on genetic control.
Genes and Cancer
There are two types of germline (constitutional DNA) genetic alterations which predispose to cancer [17] . Some germline genetic loci predispose directly to the disease. These single inherited genetic traits are uncommon in the population and, thus, carry with them low population attributable risks, even though individuals with these genetic traits may have a high absolute risk of developing the disease. One such candidate gene for prostate cancer has been located on 1q (24) (25) , although controversy exists as to its relevance [18] .
Much more common are susceptibility genes with low absolute risk, but possibly high population attributable risk, as the higher risk genotype may be quite common in the population. These types of genes, such as those involved in androgen metabolism as discussed below, affect risk of cancer indirectly. Relevant sequence variants in several such genes in a common androgen pathway could give rise to a 'polygenic' etiology of cancer, thereby allowing the identification of individuals with high-or low-risk polygenic profiles [17] .
Establishing a Genetic Model for Prostate Cancer
In developing a polygenic model of prostate carcinogenesis, genes involved in androgen biosynthesis, androgen activation and inactivation, and androgen transport as well as the 'downstream' genes transactivated through the AR, are all of interest (table 1) . We have begun to explore a few such genes which: (1) encode products which potentially play an important role in inducing androgen stimulation of the prostate; (2) are polymorphic and (3) show substantial allelic variation among the racial-ethnic groups of greatest interest in terms of prostate cancer risk. There are two pathways through which androgens are metabolized in the testes. The 5‰ pathway is more common in humans whereas the 4‰ pathway is common in rodents [19] . The major metabolic androgen pathways pertaining to the prostate and the relevant sites of activity of the gene products of current interest as they pertain to the prostate are illustrated in figure 1 .
We have initially focused on two genes in this pathway, the steroid 5·-reductase type II (SRD5A2) gene, which encodes the enzyme responsible for conversion of T to the metabolically more active (in terms of AR affinity) DHT, and the AR gene, which encodes the AR allowing for androgen binding and transport, DNA binding and transactivation of androgen-responsive genes.
Our primary initial goal was to demonstrate that the polymorphic markers of interest were related to prostate cancer risk, that the prevalence of high-risk genotypes correlates with the racial-ethnic variation in prostate cancer incidence and, when appropriate, that the genotypic variation correlates in the anticipated direction with biochemical variation in vivo. We have generally utilized the large Hawaii and Los Angeles multiethnic cohort for this series of studies [20] . This cohort of 215,251 individuals from five major ethnic groups was initiated in 1993.
Steroid 5·-Reductase Type II (SRD5A2) Gene
There are two distinct steroid 5·-reductase enzymes encoded by two different genes. There is only 50% homology in amino acid sequence between the two enzymes and The 5‰ is more common in humans and rabbits and the 4‰ pathway is more common in rodents [19] . Cell proliferation a clear distinction in optimal pH. The type II enzyme encoded by the SRD5A2 gene on chromosome 2p contains five exons and is active primarily in the prostate and in genital skin [21] . Germline mutations of SRD5A2 have been identified in a highly inbred kindred in the Dominican Republic [22] . Boys with this mutated gene are phenotypically female and have a persistent vaginal pouch until puberty, at which time there is some phallic enlargement and development of some secondary sex characteristics, but the prostate remains highly underdeveloped. We sequenced the SRD5A2 gene in a sample of men with either high or low circulating levels of 3·-androstanediol glucuronide (the biochemical serologic correlate of prostatic 5·-reductase activity in vivo) using single-strand conformation polymorphism (SSCP) followed by sequencing of any aberrant SSCP patterns identified. We identified seven missense mutations which resulted in an altered amino acid, and six nucleotide substitutions that were either silent (no amino acid change) or intronic. Only one of the seven missense mutations, the valine to leucine substitution at codon 89 (V89L substitution), was common among healthy men in the cohort [23] . We examined the distribution of this polymorphic marker in 286 control men from four racial-ethnic groups. The valine 89 homozygote genotype (VV) was the most common genotype in both African-Americans (59%) and whites (52%), but was much less common in Chinese and Japanese (30%). On the other hand, the leucine 89 homozygote genotype (LL) was most common in Chinese and Japanese (19%), but accounted for the genotype of only 10% of whites and 3% of African-Americans (the differences between Asians and the other two groups were highly statistically significant (p ! 0.001)) [22] . After controlling for race-ethnicity, there was a strong correlation between the V89L genotype and circulating levels of androstanediol glucuronide.
A second missense mutation resulting in an alanine to threonine substitution at codon 49 (A49T) was uncommon in healthy men, so we did not at first evaluate it further in terms of prostate cancer risk. However, even though the allele frequency of this A49T mutation was only 0.5% in healthy high-risk African-American men and only 1.8% in healthy low-risk Latino men, it was considerably more common in men with prostate cancer, especially those presenting with advanced (i.e., clinically significant) disease [24] . Among African-Americans, the prevalence was 0.9% for men with early stage, low-grade prostate cancer and 6.1% for more advanced disease resulting in relative risk estimates of 1.9 and 10.6, respectively (p = 0.001 for presence of the T allele); for Latinos, the comparable figures were 4.6 and 7.0%, respectively, with resultant relative risks of 2.1 and 4.5 (p = 0.04 for presence of the T allele). We concluded that this single mutation, while very uncommon in healthy men, may actually be associated with nearly 10% of all advanced prostate cancers in these two populations [24] .
The AR Gene
The AR gene, located on the long arm of the X-chromosome, codes for a transcription factor within the superfamily of steroid receptors. The large exon 1 encodes the transactivation domain that mediates target gene transcriptional activation. Exon 1 also encodes two polymorphic polyamino acid tracts, a poly-Q (CAG) n and a poly-G (GGC) n [25] .
We have focused our attention on the (CAG) n sequence, since an expansion of this repeat is the cause of a rare, X-linked adult-onset motor neuron disease, spinal and bulbar muscular atrophy, or Kennedy's disease [26] , associated with low virilization, reduced sperm production, testicular atrophy, and reduced fertility [26] . More than double the average number of CAG repeats are found in the AR of such patients. Among otherwise healthy men impaired sperm production and male infertility are associated with CAG repeat sizes in the long end of the 'normal' size distribution [27] . Thus AR activity appears to be negatively correlated with CAG size. Consistent with this notion, we hypothesized [28] and subsequently provided evidence [29] that shorter alleles of the (CAG) n could be associated with prostate cancer. Two independent epidemiological studies confirmed our original observations [30, 31] , and a further two studies [32, 33] identified phenotypic subgroups among prostate cancer cases on the basis of CAG repeats.
We [34] and others [35] have observed an excess risk of prostate cancer in men with prostate cancer-affected brothers compared to those with prostate cancer-affected fathers. We have interpreted this to indicate either an Xlinked or a recessive model of prostate cancer risk inheritance. Although the AR gene would be a strong candidate to explain such an inheritance pattern, a recent report found a strong linkage to the X chromosome far removed from the AR gene (Xq27-28), following a genome wide search in a large number of prostate cancer pedigrees [36] . Nonetheless, we have continued to pursue the issue of hereditary prostate cancer linked to the AR gene among African-American men. In this analysis, we analyzed a third polymorphic marker, a StuI single nucleotidepolymorphism [37] (silent) at codon 211 (G1733A), roughly halfway between the two satellites. The S1 allele (uncut by the restriction enzyme) was associated with a statistically significant nearly 3-fold increased risk of prostate cancer among men under age 65 years. Moreover, an excess proportion of this allele (12 of 14, 86%) also was found among prostate cancer cases with an affected brother; the corresponding proportion among control men was 58% (118 of 204) [G. Coetzee, pers. commun.] . These preliminary data indicate that in African-American men non-(CAG) n genetic variation(s) in exon 1 might contribute to hereditary prostate cancer among brothers of men with this disease. Given the substantial distance between the AR and the putative linkage in the area of Xq27-28, it seems unlikely these two observations are directly related. However, both these early provocative results suggest multiple important research pathways for further understanding the contribution of the AR or some other major X chromosome gene to prostate cancer risk.
Expanding the Model
The early experience with SRD5A2 and AR suggests that the fundamental paradigm linking genetic polymorphisms to prostate cancer risk is plausible. In order to Ross/Coetzee/Pearce/Reichardt/Bretsky/ Kolonel/Henderson/Lander/Altshuler/ Daley expand the number of potentially relevant genes and sequence variants, we have established a collaboration with Whitehead Institute/MIT, Center for Genome Research. A number of genes in the androgen pathway, as well as several others that affect cell growth through other pathways, have been selected for this project (table 1). We expect that additional candidate genes will be included. The transcribed regions of these genes are being sequenced by the Whitehead Institute/MIT, Center for Genome Research for single nucleotide polymorphisms (SNPs) [38] . We expect to identify novel SNPs and these will be incorporated, along with published SNPs, into large-scale genotyping of the prostate cancer cases and controls from the multiethnic cohort study.
The choice of genes in the androgen pathway and those associated with androgen biosynthesis and transport is biologically sound. The current epidemiologic literature suggests that these genes may play a role in prostate cancer etiology. If our findings continue to support a role for any or a combination of these genes it is possible that a prostate cancer 'risk profile' can be developed. The elucidation of such a risk profile for prostate cancer will allow for more careful screening and possibly less invasive treatment for this disease.
